AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A pharmaceutical composition comprising ~~an adequate~~ a ~~pharmaceutical~~ pharmaceutically acceptable carrier or diluent and an isolated polypeptide having greater than 95% sequence identity to the polypeptide of SEQ ID NO: 1 or ~~a sufficient amount of an element selected from the group consisting of a apolipoprotein L-1,~~ a ~~pharmaceutically active~~ fragment thereof that inhibits trypanosome infection~~, a polynucleotide encoding said polypeptide, a cell transformed by said polynucleotide and an inhibitor directed against said apolipoprotein L-1~~.

2. **(Canceled)**

3. **(Currently amended)** The pharmaceutical composition of claim ~~2~~ 1, wherein the ~~pharmaceutically~~ trypanolytically active fragment ~~of the human apolipoprotein L-1~~ is selected from the group consisting of ~~a sequence starting from the~~ amino acid 1 ~~up~~ to ~~the~~ amino acid 342 of SEQ ID NO: 1, ~~a sequence starting from the~~ amino acid 343 to ~~the~~ amino acid 398 of SEQ ID NO: 1, ~~a sequence starting from the~~ amino acid 340 ~~up~~ to ~~the~~ amino acid 398 of SEQ ID NO: 1, ~~a sequence starting from the~~ amino acid 340 ~~up~~ to ~~the~~ amino acid 362 of SEQ ID NO: 1 and ~~a sequence starting from the~~ amino acid 356 ~~up~~ to ~~the~~ amino acid 398 of ~~a human polypeptide apolipoprotein sequence of~~ SEQ ID NO: 1.

4. **(Withdrawn)** The pharmaceutical composition according to claim 1, wherein the inhibitor directed against apolipoprotein L-1 is a trypanosoma serum resistance associated polypeptide, SRA, or a pharmaceutical active fragment thereof or any molecule which mimic an interaction between the polypeptide SRA and the apolipoprotein L-1.

5. **(Withdrawn)** The pharmaceutical composition according to claim 4, wherein the pharmaceutical active fragment of the Trypanosoma polypeptide SRA is a fragment of said polypeptide, which interacts specifically with apolipoprotein L-1.

6. **(Withdrawn)** The pharmaceutical composition according to claim 4, wherein the molecule which mimic the interaction between the polypeptide SRA and the apolipoprotein L-1

is an antibody or a hyper variable portion thereof, directed against apolipoprotein L-1, which interacts with the Trypanosoma polypeptide SRA.

7. **(Withdrawn)** The pharmaceutical composition according to claim 1, wherein the inhibitor is an anti-idiotypic antibody or a hyper variable portion thereof directed against ~~the~~ an anti-apolipoprotein L-1 antibody or a hyper variable portion thereof.

8. **(Currently amended)** A method of ~~treatment and/or the prevention of diseases induced in mammals by Trypanosoma~~ ameliorating and/or preventing a Trypanosoma infection in a mammal, comprising ~~introducing~~ administering the pharmaceutical composition of Claim 1 to said ~~mammals~~ mammal.

9. **(Previously presented)** The method according to claim 8, wherein the Trypanosoma are selected from the group consisting of *Trypanosoma brucei brucei*, *Trypanosoma brucei rhodesiense* and *Trypanosoma gambiense*.

10. **(Currently amended)** The method according to claim 8 wherein said ~~disease~~ Trypanosoma infection is associated with Nagana induced in bovidae by *Trypanosoma brucei brucei*.

11. **(Canceled)**

12. **(Canceled)**

13. **(Withdrawn)** The diagnostic kit according to claim 11, wherein said inhibitor is a trypanosoma polypeptide SRA or a fragment thereof which interacts with said apolipoprotein L-1 or an antibody or a hyper variable portion thereof directed against said apolipoprotein L-1.

14. **(Withdrawn)** A non-human genetically modified mammal which is expressing a polynucleotide encoding an apolipoprotein L-1 or an active pharmaceutical fragment thereof and wherein the mammal is resistant or tolerant to diseases induced by Trypanosoma.

15. **(Withdrawn)** The mammal according to claim 14 which is a genetically modified bovidae.

16. **(Withdrawn)** The mammal according to claim 14, wherein the pharmaceutical active fragment of apolipoprotein is a sequence starting from the amino acid 1 up to the amino acid 342 .

17. **(Withdrawn)** A solid support comprising, bound to a surface of said solid support, an inhibitor directed against an apolipoprotein L-1.

18. **(Withdrawn)** A method for recovering of apolipoprotein L-1 polypeptide from a mammal, , said method comprising the steps of:

- putting into contact a sample with the solid support of claim 17,
- binding the apolipoprotein L-1 to said inhibitor, and
- eluting a contaminant of said sample, and
- eluting the apolipoprotein L-1 bound to the inhibitor from said solid support.

19. **(Withdrawn)** The pharmaceutical composition according to claim 6, wherein the antibody or a hyper variable portion thereof directed against apolipoprotein L-1 is an antibody or a hyper variable portion thereof directed against a terminal fragment of apolipoprotein L-1.

20. **(Withdrawn)** The method of Claim 8, wherein said mammal is human.

21. **(Previously presented)** The method of Claim 8, wherein said Trypanosoma is African Trypanosoma.

22. **(Withdrawn)** The non-human genetically modified mammal of Claim 14, wherein said apolipoprotein L-1 is a human polypeptide apolipoprotein L-I or an homologue of said polypeptide.

23. **(Withdrawn)** The non-human genetically modified mammal of Claim 14, wherein said Trypanosoma is *Trypanosoma brucei brucei* (Nagana).

24. **(Withdrawn)** The solid support of Claim 17, wherein said solid support is a chromatographic column.

25. **(Withdrawn)** The solid support of Claim 17, wherein said inhibitor is an antibody, the SRA polypeptide or a fragment thereof.

26. **(Withdrawn)** The solid support of Claim 17, wherein said inhibitor is adapted for the recovery of said apolipoprotein L-1.

27. **(Withdrawn)** The solid support of Claim 26, wherein said recovery is from a human body sample.

28. **(Withdrawn)** The method of Claim 18, wherein said sample is a human body sample.

29. **(Withdrawn)** The method of Claim 28, wherein said human body sample is human serum.

30. **(New)** The pharmaceutical composition of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier or diluent and an isolated polypeptide having greater than 95% sequence identity to the polypeptide of SEQ ID NO: 1.

31. **(New)** The pharmaceutical composition of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier or diluent and a fragment of a polypeptide having greater than 95% sequence identity to the polypeptide of SEQ ID NO: 1 that inhibits trypanosome infection.